Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease

Cancer Research

Volumn 72, Issue 2, 2012, Pages 516-526

  Johnson, Jackie L ^a   Pillai, Smitha ^a   Pernazza, Danielle ^a   Sebti, Saïd M ^a   Lawrence, Nicholas J ^a   Chellappan, Srikumar P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAF PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; IN VITRO STUDY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MATRIX METALLOPROTEINASE 14 GENE; MATRIX METALLOPROTEINASE 15 GENE; MATRIX METALLOPROTEINASE 9 GENE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; E2F TRANSCRIPTION FACTORS; ENZYME ASSAYS; FEMALE; GELATIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; MICE, SCID; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84862907531     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2647     Document Type: Article

References (50)

1. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009;9:785-97.
2. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 1992;6:177-85.
3. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005;24:2796-809. (Pubitemid 40638091)
4. Kinkade R, Rizwani W, Chellappan S. E2F transcription factors in cell proliferation, apoptosis, senescence and cancer. In: Kenichi Yoshida, editor. Control of cellular physiology by E2F transcription factors. Trivandrum, India: Research Signpost Press; 2007. p. 69-89.
5. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002;2:910-7. (Pubitemid 37328892)
6. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
7. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46. (Pubitemid 38167315)
8. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J 2004;23:4709-16. (Pubitemid 40069701)
9. Singh S, Johnson J, Chellappan S. Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim Biophys Acta 2010;1799:788-94.
10. Wang S, Ghosh RN, Chellappan SP. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 1998;18:7487-98. (Pubitemid 28533067)
11. Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004;24:9527-41. (Pubitemid 39391689)
12. Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 2008;68:3810-8.
13. Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, et al. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Mol Cancer Ther 2010;9:3330-41.
14. Davis RK, Chellappan S. Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer. Drug News Perspect 2008;21:331-5.
15. Pillai S, Kovacs M, Chellappan S. Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 2010;70:4931-40.
16. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
17. Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000;242:75-86. (Pubitemid 30065091)
18. Pillai S, Dasgupta P, Chellappan SP. Chromatin immunoprecipitation assays: analyzing transcription factor binding and histone modifications in vivo . Methods Mol Biol 2009;523:323-39.
19. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-17. (Pubitemid 44162330)
20. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
21. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009;124:36-45.
22. Netzel-Arnett S, Mitola DJ, Yamada SS, Chrysovergis K, Holmbeck K, Birkedal-Hansen H, et al. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002;277:45154-61. (Pubitemid 36159118)
23. Stanelle J, Stiewe T, Theseling CC, Peter M, Putzer BM. Gene expression changes in response to E2F1 activation. Nucleic Acids Res 2002;30:1859-67. (Pubitemid 34679765)
24. Ma Y, Croxton R, Moorer RL Jr., Cress WD. Identification of novel E2F1-regulated genes by microarray. Arch Biochem Biophys 2002;399:212-24. (Pubitemid 34848609)
25. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006;5:1597-601. (Pubitemid 44285243)
26. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-33.
27. D'Souza SJ, Vespa A, Murkherjee S, Maher A, Pajak A, Dagnino L. E2F-1 is essential for normal epidermal wound repair. J Biol Chem 2002;277:10626-32. (Pubitemid 34968187)
28. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
29. Slansky JE, Farnham PJ. Transcriptional regulation of the dihydrofolate reductase gene. Bioessays 1996;18:55-62.
30. Lukas J, Petersen BO, Holm K, Bartek J, Helin K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol 1996;16:1047-57.
31. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002;21:1359-69. (Pubitemid 34214501)
32. Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, et al. E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol 2010;30:524-36.
33. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, Hagan JP, et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009;462:930-4.
34. Tsai SY, Opavsky R, Sharma N, Wu L, Naidu S, Nolan E, et al. Mouse development with a single E2F activator. Nature 2008;454:1137-41.
35. Lavrrar JL, Farnham PJ. The use of transient chromatin immunoprecipitation assays to test models for E2F1-specific transcriptional activation. J Biol Chem 2004;279:46343-9. (Pubitemid 39491630)
36. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol 2001;21:6820-32. (Pubitemid 32911243)
37. Jin VX, Rabinovich A, Squazzo SL, Green R, Farnham PJ. A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data-a case study using E2F1. Genome Res 2006;16:1585-95. (Pubitemid 44878497)
38. Wells J, Graveel CR, Bartley SM, Madore SJ, Farnham PJ. The identification of E2F1-specific target genes. Proc Natl Acad Sci U S A 2002;99:3890-5. (Pubitemid 34252201)
39. Wells J, Yan PS, Cechvala M, Huang T, Farnham PJ. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene 2003;22:1445-60. (Pubitemid 36390594)
40. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008;40:1362-78.
41. Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci 1998;3:d447-8.
42. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.
43. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8. (Pubitemid 29489213)
44. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30. (Pubitemid 30616366)
45. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29:78-86. (Pubitemid 34226522)
46. Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45. (Pubitemid 36437920)
47. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39:1948-56. (Pubitemid 37311193)
48. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9. (Pubitemid 37139832)
49. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769-81. (Pubitemid 39565156)
50. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008;68:5104-12.